Department of Gastroenterology and Hematology, Faculty of Medicine, Miyazaki University, Kiyotake, Miyazaki, Japan.
Int J Hematol. 2010 Sep;92(2):320-5. doi: 10.1007/s12185-010-0653-2. Epub 2010 Aug 10.
Janus kinase 1 (JAK1) and JAK3 plays a critical role in lymphocyte proliferation and differentiation. Somatic JAK1 mutations are found in 18% of adult precursor T acute lymphoblastic leukemias and somatic JAK3 mutations are found in 3.3% of cutaneous T cell lymphomas. Some of the mutations are confirmed as a gain-of-function mutation and are assumed to be involved in leukemogenesis. Adult T cell leukemia/lymphoma (ATLL) is a type of T cell neoplasm, and activation of JAK/STAT pathways is sometimes observed in them. We investigated JAK1 and JAK3 mutations in 20 ATLL patients. No JAK1 mutations were found, and five types of single nucleotide polymorphisms were observed in 12 cases, whose frequencies almost match those in Asian populations. As for JAK3, a synonymous mutation was found in one case. JAK1 and JAK3 mutations are unlikely involved in the leukemogenesis of ATLL.
Janus 激酶 1(JAK1)和 JAK3 在淋巴细胞增殖和分化中发挥着关键作用。体细胞 JAK1 突变发生在 18%的成人前体 T 急性淋巴细胞白血病中,而体细胞 JAK3 突变发生在 3.3%的皮肤 T 细胞淋巴瘤中。一些突变被确认为功能获得性突变,被认为参与了白血病的发生。成人 T 细胞白血病/淋巴瘤(ATLL)是一种 T 细胞肿瘤,其中 JAK/STAT 途径的激活有时会被观察到。我们研究了 20 例 ATLL 患者的 JAK1 和 JAK3 突变。未发现 JAK1 突变,在 12 例中观察到 5 种单核苷酸多态性,其频率几乎与亚洲人群相匹配。至于 JAK3,在一个病例中发现了一个同义突变。JAK1 和 JAK3 突变不太可能参与 ATLL 的白血病发生。